Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review.
anti-programmed cell death protein-1
immune checkpoint inhibitors
immune-related adverse events
intrahepatic cholangiocarcinoma
type 1 diabetes
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
25
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors, widely used in the treatment of malignancies, can improve the prognosis of patients, while it also can induce various immune-related adverse events, and type 1 diabetes induced by anti-programmed cell death protein-1 is a rare but severe complication. Here we reported a case of type 1 diabetes induced by anti-PD-1 which was to treat intrahepatic cholangiocarcinoma. The case was a 61-year-old female who developed diabetes and ketoacidosis symptoms at the 16th week after anti-PD-1 therapy. Her blood glucose was 30.32 mmol/L, HBA1c was 8.10%, and C-peptide was <0.10 ng/ml. The patient was diagnosed as fulminant type 1 diabetes mellitus complicated with ketoacidosis induced by anti-PD-1, and was treated with massive fluid rehydration, intravenous infusion of insulin and correction of acid-base electrolyte disorder. Hepatectomy was performed after stabilization, and the patient was treated with long-term insulin. Through the case report and literature review, this study aims to improve oncologists' understanding of anti-PD-1 induced type 1 diabetes, so as to make early diagnosis and treatment of the complications and ensure medical safety.
Identifiants
pubmed: 35784237
doi: 10.3389/fpubh.2022.917679
pmc: PMC9243496
doi:
Substances chimiques
Insulins
0
Types de publication
Case Reports
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
917679Informations de copyright
Copyright © 2022 Zheng, Wang, Li, Wu, Chen and Zhou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Postgrad Med. 2020 Mar;132(2):206-214
pubmed: 31876444
JAMA Oncol. 2016 Oct 01;2(10):1346-1353
pubmed: 27367787
Diabetes Care. 2020 Dec;43(12):3106-3109
pubmed: 33051330
Chin Med J (Engl). 2020 Nov 5;133(21):2595-2598
pubmed: 32842016
Cell Immunol. 2016 Dec;310:27-41
pubmed: 27660198
J Clin Invest. 2020 Jan 2;130(1):51-61
pubmed: 31895048
Colorectal Dis. 2013 Jan;15(1):27-33
pubmed: 22594556
Diabetes. 2018 Aug;67(8):1471-1480
pubmed: 29937434
Cancer Immunol Immunother. 2017 Nov;66(11):1399-1410
pubmed: 28634815
Anticancer Res. 2009 Nov;29(11):4683-7
pubmed: 20032420
Diabet Med. 2019 Sep;36(9):1075-1081
pubmed: 31199005
J Immunother. 2018 Jun;41(5):232-240
pubmed: 29481423
JAMA Oncol. 2018 Feb 01;4(2):173-182
pubmed: 28973656
J Oncol Pharm Pract. 2015 Oct;21(5):380-3
pubmed: 24781450
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-3154
pubmed: 29955867
BMJ Case Rep. 2021 Mar 24;14(3):
pubmed: 33762290
Clin Med (Lond). 2020 Jul;20(4):417-423
pubmed: 32675150
Tohoku J Exp Med. 2016;239(2):155-8
pubmed: 27297738
Diabetes Metab. 2021 May;47(3):101193
pubmed: 33010422
Front Med (Lausanne). 2020 Aug 28;7:368
pubmed: 32984358
Nat Clin Pract Endocrinol Metab. 2007 Jan;3(1):36-45; quiz 2p following 69
pubmed: 17179928
Diabetes. 2010 Aug;59(8):1966-73
pubmed: 20484136
Nat Rev Endocrinol. 2017 Apr;13(4):195-207
pubmed: 28106152
Niger J Clin Pract. 2016 Nov-Dec;19(6):704-708
pubmed: 27811438
J Natl Cancer Inst. 2016 Dec 31;109(4):
pubmed: 28040701
J Pharm Pract. 2021 Feb;34(1):133-140
pubmed: 31269868
Acta Diabetol. 2019 Apr;56(4):441-448
pubmed: 30284618
Horm Metab Res. 2019 Mar;51(3):145-156
pubmed: 30861560
Oncologist. 2017 Oct;22(10):1232-1237
pubmed: 28652280
Endocr Relat Cancer. 2017 Dec;24(12):T331-T347
pubmed: 29025857
J Thorac Oncol. 2017 May;12(5):e41-e43
pubmed: 28017788
Eur J Cancer. 2016 Jun;60:190-209
pubmed: 27085692
Endocr Rev. 2019 Feb 1;40(1):17-65
pubmed: 30184160
Eur J Endocrinol. 2019 Sep;181(3):363-374
pubmed: 31330498
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Clin Diabetes Endocrinol. 2019 Jan 22;5:1
pubmed: 30693099
Transl Lung Cancer Res. 2020 Apr;9(2):379-388
pubmed: 32420079
Medicine (Baltimore). 2019 Nov;98(45):e17832
pubmed: 31702638
BMJ Case Rep. 2019 Aug 26;12(8):
pubmed: 31451458
ESMO Open. 2021 Feb;6(1):100011
pubmed: 33399077
BMJ Case Rep. 2016 Nov 23;2016:
pubmed: 27881588